查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087385

乾癬治療市場：2026-2032年全球市場預測（依治療分類、給藥途徑、疾病嚴重程度、臨床症狀、治療方案、患者年齡層及最終用戶分類）

Psoriasis Therapeutics Market by Therapeutic Class, Route Of Administration, Disease Severity, Clinical Presentation, Therapy Regimen, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乾癬治療市場將成長至 372.6 億美元，複合年成長率為 4.18%。

主要市場統計數據
基準年 2025 279.7億美元
預計年份：2026年 291億美元
預測年份 2032 372.6億美元
複合年成長率 (%) 4.18%

銀屑病藥物針對的是一種影響皮膚、指甲和關節的慢性免疫介導性發炎性疾病，該疾病會降低患者的生活品質。世界衛生組織（WHO）將乾癬認定為嚴重的非傳染性疾病，研究報告的盛行率範圍約為0.09%至11.4%，這反映了遺傳因素、氣候、診斷方法和醫療保健報告系統等方面的差異。

治療方案包括外用皮質類固醇和維生素D類似物、照光治療、傳統全身用藥（如胺基甲基葉酸和Cyclosporine）、口服標靶治療以及抑制腫瘤壞死因子（TNF）、白細胞介素-12/23、白細胞介素-17和白細胞介素-23訊號通路的生物製劑。銀屑病治療市場的成長受到以下因素的影響：早期專科轉診、標靶治療、合併症篩檢、生物相似藥的引入以及能夠持續改善皮膚症狀且給藥方便的藥物。

銀屑病治療前景的變革性變化

銀屑病治療的趨勢正從控制症狀轉向基於免疫學的精準治療和長期疾病管理。美國皮膚病學會、美國國家銀屑病基金會和歐洲皮膚病協會等機構的指南建議，應根據病情嚴重程度選擇治療方案，評估乾癬性關節炎的風險，並在疾病累及範圍超出體表面積時逐步過渡到系統性治療。

人工智慧的累積影響

人工智慧正在對銀屑病治療的各個階段產生日益顯著的影響，從藥物研發和診斷到臨床試驗設計和患者支持。在臨床實踐中，機器學習能夠識別發炎特徵，根據患者的治療反應可能性進行分層，並分析僅靠人工審核難以處理的複雜影像和基因組數據。

關鍵區域洞察

由於中國、印度、日本、韓國和澳洲等國皮膚科醫療服務、臨床研究能力和先進療法醫保覆蓋範圍的擴大，亞太地區的戰略重要性日益凸顯。該地區不僅存在大量未接受治療或治療不足的患者，免疫介導疾病的診斷數量也在增加，但都市區之間在治療費用承擔能力和獲得專科醫療服務方面仍然存在差距。

關鍵的群體特定見解

在東協市場，隨著新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國的都市區醫療網路不斷擴展，對銀屑病診斷和系統治療的需求日益成長。由於東協各國醫療資源取得差異顯著，分級定價、醫師培訓、遠距皮膚科診療支援以及公私合營對於擴大治療覆蓋範圍至關重要。

主要國家的概況

美國在銀屑病治療領域發揮核心作用，這得益於其生物製藥的高使用率、活躍的專科藥房管道以及積極參與臨床試驗。在加拿大，基於實證醫學的保險報銷和省級准入決策受到重視；而在墨西哥和巴西，專科醫療保健正在發展，但它們仍在努力平衡生物製藥的可及性與公共預算的限制以及醫療服務區域差異之間的關係。

為行業領導者提供的實用建議

行業領導者應優先考慮能夠將改善皮膚症狀、減輕瘙癢、監測關節症狀、安全性、給藥便利性和提高生活品質聯繫起來的差異化證據。競爭優勢越來越依賴在隨機臨床試驗和真實世界臨床環境中證明產品價值，包括治療維持率、藥物轉換傾向和病患報告結局 (PRO)。

調查方法

本執行摘要是根據檢驗資訊來源的系統性回顧，這些資料包括皮膚病治療指南、法規核准流程、同行評審的臨床證據、公共衛生資訊、特定治療組的安全資訊以及醫療保健系統中的准入情況。重點在於可重複性、臨床相關性以及與乾癬治療決策相符的證據。

結論

乾癬治療正邁入一個更加精準、循證的時代，其特點是免疫學創新、支付方課責、數位醫療的整合以及真實世界臨床結果日益重要。儘管生物製藥和口服標靶治療已顯著改善了疾病控制前景，但藥物可近性、經濟負擔、用藥依從性和治療順序仍然是亟待解決的關鍵挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 銀屑病治療市場：依治療分類

  • 生物製劑
  • 照光治療
    • 準分子雷射
    • 窄頻UVB
    • PUVA
  • 低分子化合物
    • JAK抑制劑
    • PDE4抑制劑
  • 外用製劑
    • Calcineurin抑制劑
    • 皮質類固醇
    • 維生素D類似物

第8章 銀屑病治療市場：依給藥途徑分類

  • 注射藥物
    • 自動注射器
    • 預填充式注射器
    • 管瓶
  • 口服
    • 膠囊
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 軟膏

第9章 銀屑病治療市場：依疾病嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第10章：銀屑病治療市場：依臨床症狀分類

  • 斑塊型乾癬
  • 水滴狀乾癬
  • 反向銀屑病
  • 膿皰型乾癬
  • 紅皮病型乾癬

第11章 銀屑病治療市場：依治療方案分類

  • 單藥治療
  • 聯合治療

第12章 銀屑病治療市場：依患者年齡層別分類

  • 成人
  • 兒童
  • 老年人

第13章 銀屑病治療市場：依最終用戶分類

  • 診所
  • 皮膚病中心
  • 醫院

第14章 銀屑病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 銀屑病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 銀屑病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc.
  • Arcutis Biotherapeutics Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celltrion Inc.
  • Dermavant Sciences Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sandoz Group AG
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Zydus Lifesciences Ltd.
Product Code: MRR-035AB9C0DA46

The Psoriasis Therapeutics Market is projected to grow by USD 37.26 billion at a CAGR of 4.18% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.97 billion
Estimated Year [2026] USD 29.10 billion
Forecast Year [2032] USD 37.26 billion
CAGR (%) 4.18%

Psoriasis therapeutics address a chronic, immune-mediated inflammatory disease that affects skin, nails, joints, and quality of life. The World Health Organization recognizes psoriasis as a serious noncommunicable disease, with prevalence reported across studies from approximately 0.09% to 11.4%, reflecting differences in genetics, climate, diagnosis, and health-system reporting.

The treatment landscape spans topical corticosteroids and vitamin D analogs, phototherapy, conventional systemic agents such as methotrexate and cyclosporine, oral targeted therapies, and biologics that inhibit tumor necrosis factor, interleukin-12/23, interleukin-17, and interleukin-23 pathways. Growth in psoriasis therapeutics is being shaped by earlier specialist referral, treat-to-target care, comorbidity screening, biosimilar adoption, and demand for durable skin clearance with convenient dosing.

Transformative Shifts in the Psoriasis Treatment Landscape

The psoriasis therapeutics landscape is shifting from symptom control toward precision immunology and long-term disease control. Dermatology guidelines from organizations such as the American Academy of Dermatology, National Psoriasis Foundation, and European dermatology bodies support severity-based treatment selection, assessment of psoriatic arthritis risk, and escalation to systemic therapy when disease burden extends beyond body surface area alone.

Biologic innovation has raised expectations for Psoriasis Area and Severity Index improvement, while oral small molecules are expanding options for patients who prefer non-injectable therapy. At the same time, payer scrutiny, biosimilar competition, step-therapy policies, and real-world evidence requirements are transforming commercial strategy, making access, adherence, safety monitoring, and value demonstration central to therapeutic success.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing psoriasis therapeutics across discovery, diagnosis, trial design, and patient support. In research settings, machine learning can help identify inflammatory signatures, stratify patients by likely response, and analyze imaging or genomic datasets that are too complex for manual review alone.

In clinical and commercial operations, AI-enabled tools support lesion assessment from digital images, remote monitoring, adherence prompts, pharmacovigilance signal detection, and real-world evidence generation. The cumulative impact is not a replacement for dermatologists; it is a more data-rich care pathway that can improve triage, personalize treatment sequencing, and reduce delays between inadequate response and therapy optimization.

Key Regional Insights

Asia-Pacific is gaining strategic relevance as China, India, Japan, South Korea, and Australia expand dermatology access, clinical research capacity, and reimbursement pathways for advanced therapies. The region combines large untreated or undertreated populations with rising diagnosis of immune-mediated diseases, although affordability and specialty-care availability remain uneven across urban and rural settings.

North America remains a highly developed psoriasis therapeutics environment, led by the United States and Canada, where biologics, oral targeted therapies, specialty pharmacies, and patient-support programs are well established. Europe is shaped by strong dermatology guideline adoption, health technology assessment, national reimbursement review, and biosimilar utilization, while the European Union supports harmonized regulatory standards and post-marketing safety expectations.

Latin America, led by Brazil and Mexico, shows demand for accessible systemic and biologic therapy as public and private systems improve specialty coverage. The Middle East, particularly Gulf markets, is supported by investment in specialty care and biologic access, while Africa remains more constrained by diagnosis gaps, out-of-pocket costs, specialist shortages, and limited access to advanced immunology therapies.

Key Group Insights

ASEAN markets show rising demand for psoriasis diagnosis and systemic treatment as urban healthcare networks expand in countries such as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. Access varies widely across the group, making tiered pricing, physician education, teledermatology support, and public-private collaboration important for broader treatment penetration.

The GCC benefits from high healthcare investment, specialist hospital networks, and increasing adoption of biologic therapy, although formulary inclusion and national procurement policies influence uptake. The European Union provides a structured environment for centralized approvals, pharmacovigilance, clinical guideline alignment, and biosimilar competition, which supports clinical confidence while intensifying price negotiation.

BRICS countries combine large patient pools with heterogeneous reimbursement, local manufacturing priorities, and growing demand for cost-effective immunology care. G7 countries represent mature evidence-driven markets with strong regulatory oversight and demand for real-world outcomes, while NATO member markets overlap significantly with North American and European systems where supply-chain resilience, cybersecurity, and healthcare infrastructure reliability influence therapeutic continuity.

Key Country Insights

The United States is central to psoriasis therapeutics because of high biologic utilization, active specialty pharmacy channels, and robust clinical trial participation. Canada emphasizes evidence-based reimbursement and provincial access decisions, while Mexico and Brazil are expanding specialist care but continue to balance biologic access with public-budget constraints and uneven regional coverage.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine guideline-based dermatology care with strong payer assessment, biosimilar use, and registry-driven evidence generation. Russia presents demand for systemic treatment but faces access variability, reimbursement complexity, and supply-chain pressures that can affect continuity of advanced therapies.

China and India offer large patient populations and growing dermatology infrastructure, with affordability, local evidence generation, and expanding clinical research shaping adoption. Japan, South Korea, and Australia have advanced regulatory systems, high specialty-care standards, and increasing use of biologics and oral targeted agents, making them important reference markets across Asia-Pacific.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence that links skin clearance, itch reduction, joint-symptom monitoring, safety, dosing convenience, and quality-of-life improvement. Competitive advantage increasingly depends on proving value across both randomized clinical trials and real-world care settings, including persistence, switching patterns, and patient-reported outcomes.

Organizations should also strengthen market access planning before launch, develop biosimilar-response strategies, invest in patient adherence programs, and build compliant AI-enabled tools for dermatology workflows. Partnerships with dermatology networks, payers, specialty pharmacies, and patient organizations can improve diagnosis, persistence, and equitable access.

Research Methodology

This executive summary is based on a structured review of validated sources, including dermatology treatment guidelines, regulatory pathways, peer-reviewed clinical evidence, public-health information, therapy-class safety information, and health-system access patterns. Emphasis was placed on evidence that is reproducible, clinically relevant, and aligned with psoriasis therapeutic decision-making.

The analysis evaluates therapies by mechanism of action, route of administration, clinical utility, safety considerations, reimbursement environment, regional access, and technology impact. Insights are triangulated across clinical, commercial, regulatory, and patient-care dimensions to support strategic planning in the psoriasis therapeutics landscape without relying on market sizing, market share, or forecasting.

Conclusion

Psoriasis therapeutics are entering a more precise, evidence-intensive era defined by immunology innovation, payer accountability, digital health integration, and the rising importance of real-world outcomes. Biologics and oral targeted therapies have changed expectations for disease control, but access, affordability, adherence, and treatment sequencing remain decisive issues.

Organizations that combine strong clinical differentiation with regional access strategy, AI-enabled evidence generation, and patient-centered support will be best positioned to compete. The next phase of psoriasis care will reward therapies and services that deliver durable clearance, safety confidence, convenience, and measurable value across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Psoriasis Therapeutics Market, by Therapeutic Class

  • 7.1. Biologics
  • 7.2. Phototherapy
    • 7.2.1. Excimer Laser
    • 7.2.2. Narrowband Uvb
    • 7.2.3. Puva
  • 7.3. Small Molecules
    • 7.3.1. JAK Inhibitors
    • 7.3.2. PDE4 Inhibitors
  • 7.4. Topicals
    • 7.4.1. Calcineurin Inhibitors
    • 7.4.2. Corticosteroids
    • 7.4.3. Vitamin D Analogues

8. Psoriasis Therapeutics Market, by Route Of Administration

  • 8.1. Injectable
    • 8.1.1. Auto-Injector
    • 8.1.2. Pre-Filled Syringe
    • 8.1.3. Vial
  • 8.2. Oral
    • 8.2.1. Capsule
    • 8.2.2. Tablet
  • 8.3. Topical
    • 8.3.1. Cream
    • 8.3.2. Gel
    • 8.3.3. Ointment

9. Psoriasis Therapeutics Market, by Disease Severity

  • 9.1. Mild
  • 9.2. Moderate
  • 9.3. Severe

10. Psoriasis Therapeutics Market, by Clinical Presentation

  • 10.1. Plaque Psoriasis
  • 10.2. Guttate Psoriasis
  • 10.3. Inverse Psoriasis
  • 10.4. Pustular Psoriasis
  • 10.5. Erythrodermic Psoriasis

11. Psoriasis Therapeutics Market, by Therapy Regimen

  • 11.1. Monotherapy
  • 11.2. Combination Therapy

12. Psoriasis Therapeutics Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Pediatric
  • 12.3. Geriatric

13. Psoriasis Therapeutics Market, by End User

  • 13.1. Clinics
  • 13.2. Dermatology Centers
  • 13.3. Hospitals

14. Psoriasis Therapeutics Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Psoriasis Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Psoriasis Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Almirall S.A.
  • 18.3. Amgen Inc.
  • 18.4. Arcutis Biotherapeutics Inc.
  • 18.5. AstraZeneca PLC
  • 18.6. Aurobindo Pharma Ltd.
  • 18.7. Biogen Inc.
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Bristol Myers Squibb Company
  • 18.10. Celltrion Inc.
  • 18.11. Dermavant Sciences Ltd.
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Eli Lilly and Company
  • 18.14. Fresenius Kabi AG
  • 18.15. Glenmark Pharmaceuticals Ltd.
  • 18.16. Incyte Corporation
  • 18.17. Intas Pharmaceuticals Ltd.
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. LEO Pharma A/S
  • 18.20. Merck & Co. Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Sandoz Group AG
  • 18.24. STADA Arzneimittel AG
  • 18.25. Sun Pharmaceutical Industries Ltd.
  • 18.26. Takeda Pharmaceutical Company Limited
  • 18.27. UCB S.A.
  • 18.28. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHOTOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHOTOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHOTOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EXCIMER LASER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EXCIMER LASER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EXCIMER LASER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NARROWBAND UVB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NARROWBAND UVB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NARROWBAND UVB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PUVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PUVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PUVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TOPICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TOPICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TOPICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTO-INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTO-INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTO-INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRE-FILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRE-FILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PRE-FILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OINTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OINTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. GCC PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 235. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. G7 PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 279. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 280. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. NATO PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 286. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 291. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 292. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 293. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 294. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 346. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 348. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 349. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 352. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DISE